Effects of permeation of plasma proteins in diabetic patients.
A within-person trial in 35 diabetic subjects investigated the effect of six months' administration of 750 mg of calcium dobesilate daily on the erythrocyte sedimentation rate, erythrocyte and leucocyte counts, platelet aggregation, blood cholesterol and triglyceride concentrations, total serum protein concentration, electrophoretically determined serum proteins fractions, and the escape rate of intravenously injected 131-I-albumin. Significant increases in intravenous retention of 131-I-albumin, serum albumin and beta-globulin fractions, and total serum protein concentration resulted. No change in the remaining variables was detected. The results suggest that calcium dobesilate reduces pathologically increased transcapillary escape rate in diabetes mellitus.
D001557:Benzenesulfonates / Q000627:therapeutic use*; D001798:Blood Proteins / Q000378:metabolism*; D001799:Blood Sedimentation; D002123:Calcium Dobesilate / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000503:physiopathology; D004906:Erythrocyte Count; D005500:Follow-Up Studies; D006801:Humans; D007958:Leukocyte Count; D008875:Middle Aged; D010539:Permeability; D010974:Platelet Aggregation; D014280:Triglycerides / Q000097:blood
D001557:Benzenesulfonates; D001798:Blood Proteins; D014280:Triglycerides; D002123:Calcium Dobesilate; D002784:Cholesterol